The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.
Lymphoma is a highly common malignant tumor in Asia. For specific extra-abdominal sites or rare pathological subtypes of lymphoma, traditional chemotherapy protocols often cannot provide satisfactory results for patients. This study aims to retrospectively collect clinical information on patients with extranodal lymphoma or rare pathological subtype lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best treatment strategy for these lymphomas in the real-world population.
Study Type
OBSERVATIONAL
Enrollment
10,000
No interventions need to be specified for this study
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Overall Survival (OS)
Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
Time frame: Baseline up to data cut-off (up to approximately 1 year)
Progression Free Survival (PFS)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Time frame: Baseline up to data cut-off (up to approximately 1 year)
Clinical characteristics form
Clinical characteristics from data filled into registry forms by physicians and data managers, including but not limited to values of lactate dehydrogenase, clinical stage, performance status, age ≥ 60 years and number and location of extranodal localizations.
Time frame: Baseline up to data cut-off (up to approximately 1 year)
Biological characteristics form
Biological characteristics from data filled into registry forms by physicians and data managers, such as immunohistochemical differences and genetic mutation characteristics of non-hodgkin´s lymphomas.
Time frame: Baseline up to data cut-off (up to approximately 1 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.